ABVC BioPharma (ABVC) FDA Approvals $2.75 +0.35 (+14.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.78 +0.04 (+1.27%) As of 08/1/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share FDA Events Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC BioPharma's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by ABVC BioPharma (ABVC). Over the past two years, ABVC BioPharma has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ABV-1504. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. ABV-1504 FDA Regulatory Events ABV-1504 is a drug developed by ABVC BioPharma for the following indication: For Its Natural MDD Treatment. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - May 9,2025Provided Update Drug: ABV-1504Announced Date: May 9, 2025Indication: For Its Natural MDD TreatmentAnnouncementABVC BioPharma, Inc announced that the Japan Patent Office has granted a new patent protection for its Major Depressive Disorder (MDD) candidate, ABV-1504.Read Announcement ABVC BioPharma FDA Events - Frequently Asked Questions Has ABVC BioPharma received FDA approval? As of now, ABVC BioPharma (ABVC) has not received any FDA approvals for its therapy in the last two years. What drugs has ABVC BioPharma submitted to the FDA? In the past two years, ABVC BioPharma (ABVC) has reported FDA regulatory activity for ABV-1504. What is the most recent FDA event for ABVC BioPharma? The most recent FDA-related event for ABVC BioPharma occurred on May 9, 2025, involving ABV-1504. The update was categorized as "Provided Update," with the company reporting: "ABVC BioPharma, Inc announced that the Japan Patent Office has granted a new patent protection for its Major Depressive Disorder (MDD) candidate, ABV-1504." What conditions do ABVC BioPharma's current drugs treat? Currently, ABVC BioPharma has one therapy (ABV-1504) targeting the following condition: For Its Natural MDD Treatment. More FDA Event Resources from MarketBeat FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Eupraxia Pharmaceuticals FDA Events DiaMedica Therapeutics FDA Events Innate Pharma FDA Events Lyell Immunopharma FDA Events Semper Paratus Acquisition FDA Events Ventyx Biosciences FDA Events Silence Therapeutics FDA Events Instil Bio FDA Events Caribou Biosciences FDA Events CytomX Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA Events Tools Recent FDA Drug Approval Process Events This page (NASDAQ:ABVC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - May 9,2025Provided Update Drug: ABV-1504Announced Date: May 9, 2025Indication: For Its Natural MDD TreatmentAnnouncementABVC BioPharma, Inc announced that the Japan Patent Office has granted a new patent protection for its Major Depressive Disorder (MDD) candidate, ABV-1504.Read Announcement
Free ABVC Stock Alerts